Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07559929Phase 1Not Yet Recruiting

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

Role: lead

NCT07177937Phase 1Recruiting

A Study of DXC014 in Patients With Advanced Solid Tumors.

Role: lead

NCT06926283Phase 1Recruiting

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Role: lead

NCT06224855Phase 1Recruiting

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Role: lead

All 4 trials loaded